Prostate Cancer: Quo Vadis?


Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 07 06 2019
accepted: 25 06 2019
pubmed: 14 7 2019
medline: 18 12 2020
entrez: 14 7 2019
Statut: ppublish

Résumé

Utility measures are urgently needed for clinical application of new, more sensitive diagnostics to reduce the risk of excessive intervention.

Identifiants

pubmed: 31300238
pii: S0302-2838(19)30521-4
doi: 10.1016/j.eururo.2019.06.031
pii:
doi:

Types de publication

Editorial

Langues

eng

Sous-ensembles de citation

IM

Pagination

709-711

Informations de copyright

Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Christopher J Logothetis (CJ)

Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: clogothe@mdanderson.org.

Ana Aparicio (A)

Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Filippos Koinis (F)

School of Medicine, University of Thessaly, Larissa, Greece.

Paul G Corn (PG)

Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Eleni Efstathiou (E)

Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH